Shun Nakamura

Shun Nakamura

Auto-generated profile, based on publicly available information

Shun Nakamura

Advanced Research Initiative, Institute of Integrated Research, Institute of Science Tokyo, Bunkyo-ku, Japan

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
SNShun Nakamura
Shun Nakamura
KIKatsumasa Irie
Katsumasa Irie
HTHiroo Tanaka
Hiroo Tanaka
KNKouki Nishikawa
Kouki Nishikawa
HSHiroshi Suzuki
Hiroshi Suzuki
YFYoshinori Fujiyoshi
Yoshinori Fujiyoshi
Tight junction is a cell adhesion apparatus functioning as barrier and/or channel in the paracellular spaces of epithelia. Claudin is the major component of tight junction and polymerizes to form tight junction strands with various morphologies that may correlate with their functions. Here we present the crystal structure of mammalian claudin-3 at 3.6 Å resolution. The third transmembrane helix of claudin-3 is clearly bent compared with that of other subtypes. Structural analysis of additional two mutants with a single mutation representing other subtypes in the third helix indicates that this helix takes a bent or straight structure depending on the residue. The presence or absence of the helix bending changes the positions of residues related to claudin-claudin interactions and affects the morphology and adhesiveness of the tight junction strands. These results evoke a model for tight junction strand formation with different morphologies – straight or curvy strands – observed in native epithelia.

1 February 2003 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
ASAkira Sakakibara
Akira Sakakibara
SHSeisuke Hattori
Seisuke Hattori
SNShun Nakamura
Shun Nakamura
TKTakuya Katagiri
Takuya Katagiri
Chat (Cas/HEF1-associated signaltransducer) is a novel adaptor protein with an N-terminal Src homology-2 domain and C-terminal Cas/HEF1 association domain. We report here the molecular cloning of Chat-H, the hematopoietic isoform of Chat. Chat-H has an extended N-terminal domain besides the known Chat domain structures, suggesting a unique function of Chat-H in hematopoietic cells. Jurkat transfectants overexpressing Chat-H show a marked increase in interleukin-2 production after costimulation of T cell receptor and CD28. The degree of JNK activation is enhanced substantially in the Chat-H transfectants upon costimulation. The Src homology-2 domain mutant of Chat-H loses this signal modulating activity. Expression of the Cas/HEF1 association domain mutant exhibits a dominant negative effect on both JNK activation and interleukin-2 production. We further found that Chat-H forms a complex with Pyk2H and enhances its tyrosine 402 phosphorylation, an up-regulator of the JNK pathway. These results suggest that Chat-H positively controls T cell function via integrating the costimulatory signals.

19 November 2021 in Science Advances
Verified
Journal Article
Open access
YOYukako Oda
Yukako Oda
CTChisato Takahashi
Chisato Takahashi
SHShota Harada
Shota Harada
SNShun Nakamura
Shun Nakamura
DSDaxiao Sun
Daxiao Sun
FTFumiko Toyoshima
Fumiko Toyoshima
C-terminal alpha 1-antitrypsin peptides induce tight junction formation by activating G protein G13.

31 October 2025 in Science Advances
Verified
Journal Article
Open access
HKHiroka Kashihara
Hiroka Kashihara
HTHiroo Tanaka
Hiroo Tanaka
MKManabu Kitamata
Manabu Kitamata
GSGen Shiratsuchi
Gen Shiratsuchi
TKTatsuya Katsuno
Tatsuya Katsuno
STSachiko Tsukita
Sachiko Tsukita
The diversity of epithelial paracellular barriers, essential for various biological functions, is primarily determined by the combination of 27 claudins (Cldns) that form tight junctions (TJs). However, the basis of their functional diversity remains largely unexplored. Here, we generated complete Cldn -null mouse epithelial cells to reconstitute the TJ paracellular barrier (TJ barrier) with individual Cldns. Each Cldn establishes its respective TJ barrier, either autonomously or nonautonomously, exhibiting distinct ion conductivity and selectivity. Clustering algorithms revealed a previously unidentified classification of Cldns into four main classes with well-defined subclasses, moving beyond the conventional paracellular barrier–versus–channel-forming dichotomy. Our findings, including the in vivo Cldn dynamics, provide a framework for understanding TJ barrier diversity and plasticity, offering insights into organ-specific homeostasis and guiding therapeutic strategies targeting TJ barriers in health and disease.

24 January 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
SNShun Nakamura
Shun Nakamura
YTYukihiro Tanimura
Yukihiro Tanimura
RNRisa Nomura
Risa Nomura
HSHiroshi Suzuki
Hiroshi Suzuki
KNKouki Nishikawa
Kouki Nishikawa
YFYoshinori Fujiyoshi
Yoshinori Fujiyoshi
Pathogen mutations present an inevitable and challenging problem for therapeutics and the development of mutation-tolerant anti-infective drugs to strengthen global health and combat evolving pathogens is urgently needed. While spike proteins on viral surfaces are attractive targets for preventing viral entry, they mutate frequently, making it difficult to develop effective therapeutics. Here, we used a structure-guided strategy to engineer an inhibitor peptide against the SARS-CoV-2 spike, called CeSPIACE, with mutation-tolerant and potent binding ability against all variants to enhance affinity for the invariant architecture of the receptor-binding domain (RBD). High-resolution structures of the peptide complexed with mutant RBDs revealed a mechanism of mutation-tolerant inhibition. CeSPIACE bound major mutant RBDs with picomolar affinity and inhibited infection by SARS-CoV-2 variants in VeroE6/TMPRSS2 cells (IC 50 4 pM to 13 nM) and demonstrated potent in vivo efficacy by inhalation administration in hamsters. Mutagenesis analyses to address mutation risks confirmed tolerance against existing and/or potential future mutations of the RBD. Our strategy of engineering mutation-tolerant inhibitors may be applicable to other infectious diseases.

1 June 2008 in Neuroscience Letters
Verified
Journal Article
Closed access
TMToshinori Masutani
Toshinori Masutani
KTKastutoshi Taguchi
Kastutoshi Taguchi
HKHaruko Kumanogoh
Haruko Kumanogoh
SNShun Nakamura
Shun Nakamura
SMShohei Maekawa
Shohei Maekawa